VolitionRx (NYSE:VNRX) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of VolitionRx (NYSE:VNRX) in a report issued on Saturday morning. The firm issued a sell rating on the stock.

Separately, Benchmark reaffirmed a “hold” rating on shares of VolitionRx in a research report on Friday, August 16th.

VolitionRx Stock Down 4.2 %

Shares of VolitionRx stock opened at $0.70 on Friday. The firm has a market capitalization of $58.05 million, a P/E ratio of -1.52 and a beta of 1.09. VolitionRx has a 52 week low of $0.43 and a 52 week high of $1.23. The company has a 50 day moving average price of $0.67 and a 200 day moving average price of $0.69.

VolitionRx (NYSE:VNRX) last posted its quarterly earnings results on Wednesday, August 14th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.01. The company had revenue of $0.40 million during the quarter, compared to analysts’ expectations of $0.34 million. As a group, research analysts anticipate that VolitionRx will post -0.31 earnings per share for the current fiscal year.

Insider Buying and Selling

In other VolitionRx news, Director Guy Archibald Innes bought 150,000 shares of VolitionRx stock in a transaction that occurred on Tuesday, August 20th. The stock was purchased at an average price of $0.67 per share, with a total value of $100,500.00. Following the completion of the acquisition, the director now directly owns 406,683 shares in the company, valued at approximately $272,477.61. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 12.80% of the stock is owned by corporate insiders.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.